Search for: "In re: Facebook, Inc., IPO Securities and Derivative Litigation"
Results 1 - 8
of 8
Sorted by Relevance
|
Sort by Date
19 Nov 2013, 12:00 am
[viii]Complaint at 114, In Re Facebook, Inc., IPO Securities, and Derivative Litigation, 922 F.Supp.2d 445 (S.D.N.Y. 2013) (No. 12-2389). [read post]
14 Nov 2021, 7:10 am
See In re Renren, Inc., 192 A.D.3d 539, 140 N.Y.S.3d 701 (2021). [read post]
28 Dec 2016, 6:21 am
In a summary order, the panel found that a settlement provision deferring the question of common damages to be decided in a related action against Facebook and its underwriters was not required to be resolved by the district court under the PSLRA, and leaving the question open did not violate principles of finality (In re Facebook, Inc., IPO Securities and Derivative Litigation, December 27, 2016, per curiam). [read post]
16 Feb 2021, 2:23 pm
San Francisco Nov. 16, 2020), and In re Dropbox, Inc. [read post]
1 Feb 2018, 5:55 pm
This culminated in the decision in In re Trulia Shareholder Litigation, 129 A.3d 884 (Del. [read post]
4 Jan 2021, 1:26 pm
If the merger objection lawsuits are disregarded, the litigation rate translates to about 4.7%, which although below the record-level litigation rates during the period 2017 -2019 is still well above the 1996-2018 annual litigation rate of 3.0%. [read post]
8 Sep 2015, 5:08 pm
(Indeed, the Oklahoma legislature has adopted a provision mandating the shifting of fees in derivative suits.) [read post]
11 Jul 2008, 4:30 am
Part I – Spicy IP), India: Discussion of grant of Indian patents to Cipla for Fosamax derivative and Nexium derivative: (Spicy IP), India: Draft National Biotechnology Regulatory Authority Bill: (Spicy IP), Ivory Coast: Ivorians increasingly choose fake medicines on price: (Afro-IP), Mexico: New Mexican medicaments approvals regime: an early report: (IP tango), UK: Leave to appeal refused in trade mark infringement proceedings between Eli Lilly and 8PM Chemist concerning… [read post]
